Survival Status and Predictors Among Women with Advanced Stage of Cervical Cancer
Roza Teshome,Irene Yang,Edom Woldetsadik,Eshetu Girma,Melinda Higgins,Jessica Wells
DOI: https://doi.org/10.2147/ijwh.s455235
2024-04-15
International Journal of Women s Health
Abstract:Roza Teshome, 1 Irene Yang, 2 Edom Woldetsadik, 3 Eshetu Girma, 4 Melinda Higgins, 2 Jessica Wells 2 1 Department of Midwifery, School of Nursing & Midwifery, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia; 2 Nell Hodgson Woodruff School of Nursing, Emory University, Atlanta, GA, USA; 3 Department of Oncology, School of Medicine, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia; 4 Department of Preventive Medicine, School of Public Health, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia Correspondence: Roza Teshome, Tel +251-911028610, Email Background: Cervical cancer is one of the leading causes of cancer death in women, even though it is a preventable disease. Most deaths occur in low- and middle-income countries. In addition to early detection and receipt of standard treatments, survivorship is an important component of high quality of care across the cancer continuum. Objective: To assess the survival status of advanced-stage cervical cancer patients after cancer treatment has started. Methods and Materials: A one-year prospective cohort study was employed to assess the survival status of women with advanced stages of cervical cancer. A total of 180 cervical cancer patients were recruited, and the study was conducted from January 10, 2022, to September 20, 2023. Data entry and analysis were done in the SPSS 29 version. Descriptive statistics were used to examine participant characteristics. The Kaplan-Meier procedure and log rank test were used to estimate the duration of survival. Bivariate and multivariate Cox regression analyses were computed for predictor variables with survival status. Results: Patients receiving cancer treatment at FIGO stages IVA and IVB had survived by 56% and 24%, respectively, whereas patients receiving treatment at stages IIB and IIIA had survived by 100%. The estimated mean survival time at one-year follow-up was 5.706 months (95% CI: 3.785– 7.627) for patients with FIGO stage IVB, but 11.537 months (95% CI: 11.199– 11.887) for those with stages II and III (P < 0.001). Women over 60 years old had a 1.5-fold higher risk of death than those under 60 (HR: 1.482, P = 0.040). Conclusion: The one-year cumulative survival rate among advanced-stage cervical cancer patients was 77%. Major factors associated with survival were age, cancer stage, the presence of anemia, and waiting time for treatment. Keywords: survival status, advanced stage, cervical cancer, tikur anbessa specialized hospital, Ethiopia Globally, there were over 342,000 deaths and over 604,000 new cases of cervical cancer in 2020. 1 The effects of cervical cancer vary depending on the region; evidence indicates that over 85% occurs in low- and middle-income countries. 2 Sub-Saharan Africa has the greatest regional incidence and mortality rates, with higher rates in Eastern, Southern, and Middle Africa. 1 Ethiopia is likewise confronting a significant cervical cancer burden. 3 Ethiopia is expected to have 15,300 new cases of cervical cancer by 2040, up from the anticipated 7,500 occurrences in 2020. Similarly, on an annual basis, the disease's death toll will rise from 5340 in 2020 to 11,000 in 2040. 4 The main factor contributing to cervical precancerous lesions and cancer is persistent human papillomavirus infection. 5 Adenocarcinomas, which occur in the glandular columnar layer of the endocervix, account for 10% of cervical cancer cases. Squamous cell tumors, which mostly affect the transformation zone of the ectocervix, account for 90% of cervical cancer cases. 6 Worldwide cervical cancer survival rates vary and are often associated with the level of country development. 7 Additionally, cervical cancer survival rates vary by race and subregion throughout the African continent. Tumor stage, histology, geographic location, and access to high-quality healthcare all affect survival rates. 8 The tumor stage is the main indicator of the prognosis for cervical cancer. The International Federation of Gynecology and Obstetrics (FIGO) staging system for tumors is associated with overall survival and the probability of recurrence. 9 The majority of patients in developing countries, such as Ethiopia, present late and have advanced stages of cancer. Their prognosis is significantly worse and may require a combination of treatments, such as radiation, chemotherapy, and surgery. Surgery is the main treatment for cervical cancer at stage IIA or lower, whereas chemo-radiation is used to treat the cancer when it has progressed to stage IIB or ab -Abstract Truncated-
obstetrics & gynecology